Janux Therapeutics Inc (JANX)
50.82
-6.99
(-12.09%)
USD |
NASDAQ |
Jan 08, 16:00
50.53
-0.29
(-0.57%)
After-Hours: 20:00
Janux Therapeutics SG&A Expense (Quarterly): 17.67M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Rezolute Inc | 4.187M |
| Vir Biotechnology Inc | 25.74M |
| Cytokinetics Inc | 56.65M |
| Galectin Therapeutics Inc | 1.471M |
| Viking Therapeutics Inc | 13.77M |